Funding

    Portable dialysis developer Nextkidney raises more than €20m in a C round and seeks over €3m more from the crowd

    Nextkidney B.V., the Dutch medtech company behind the Neokidney portable haemodialysis device, has raised more than €20m in a C round and opened a crowdfunding campaign aiming for more than €3m on top.

    T

    The Cap Table

    11 November 20263 min read
    Portable dialysis developer Nextkidney raises more than €20m in a C round and seeks over €3m more from the crowd

    Nextkidney B.V., the Dutch medtech company behind the Neokidney portable haemodialysis device, has raised more than €20m in a C round and opened a crowdfunding campaign aiming for more than €3m on top.

    Credit: this report is based on a story first published by MenA.nl. Read the original at mena.nl.

    According to MenA.nl, Nextkidney has raised more than €20m in a new financing round. The company's announcement, carried by FONK, describes it as a C round. Alongside the round, Nextkidney has set up a crowdfunding campaign with support from Generous Minds, through which it wants to raise more than €3m in addition.

    The company

    Nextkidney was founded in 2019 from an initiative of Nierstichting (the Dutch Kidney Foundation), which is one of its shareholders, MenA.nl reports. Its product, the Neokidney, is designed as a mobile alternative to conventional haemodialysis, in which kidney patients usually spend about four hours on a dialysis machine in a hospital or dialysis centre, three times a week. The company calls it the first portable haemodialysis device.

    The deal

    The financing comes after more than ten years of technical development, safety testing and clinical research. The money will pay for the last development and testing phase, the regulatory processes and the preparation for market launch, for use in clinics as well as at home.

    In the announcement, Jan Otto Ooms of 3O Health said the promise of lower dialysis costs was part of the reason it invested in Nextkidney.

    The crowdfunding campaign gives patients, their relatives and other interested people the chance to become financially involved in the company's further development. Participation starts at €275, according to MenA.nl.

    Clinical progress

    After a pilot study in France, a larger clinical study started in early 2026 at three medical centres in the Netherlands, Belgium and France. A total of 500 haemodialysis treatments have now been carried out with the Neokidney, including at the university medical centres in Utrecht and Leiden, under the supervision of dialysis nurses.

    "After more than ten years of development we are now very close to our end goal," said Dieter Bach, Nextkidney's chief medical officer (translated from Dutch).

    What comes next

    Once it has CE marking and approval from the US Food and Drug Administration, Nextkidney expects to launch the device commercially for use in clinics at the end of 2027.

    The next step is testing independent use. In November 2026 the company starts a new study in which patients will together carry out 500 dialysis treatments without direct supervision. If that study succeeds, Nextkidney expects to bring the Neokidney to market for independent use after the fourth quarter of 2027.


    Original source: MenA.nl, "Nextkidney haalt ruim 20 miljoen euro op voor draagbare kunstnier" Also reported by: FONK, "20 miljoen opgehaald voor de draagbare kunstnier"

    T

    Written by

    The Cap Table

    Stay in the loop

    Get the biggest stories from the Dutch startup ecosystem straight to your inbox. No spam, just what matters.

    Related stories